Fractyl Health, Inc. GUTS

GUTS Company Overview

Fractyl Health, Inc. is a metabolic therapeutics company focused on developing treatments for obesity and type 2 diabetes through minimally invasive procedures and gene therapy-based approaches. The company operates within the broader metabolic disease, biotechnology, and medical device sectors, with a strategy centered on addressing insulin resistance and metabolic dysfunction rather than solely managing symptoms. Its primary revenue and development focus has historically been the advancement of procedural and therapeutic platforms intended to improve glycemic control and reduce dependence on chronic drug therapy.

The company’s core programs include Revita, an endoscopic procedural therapy designed to remodel the duodenal lining, and Rejuva, a gene therapy platform intended to deliver durable metabolic hormone expression. Fractyl Health positions itself as a differentiated player by targeting the gastrointestinal origins of metabolic disease and combining device-based intervention with biologic therapeutics. The company was founded in 2010 and evolved from an early-stage gastrointestinal device developer into a broader metabolic therapeutics platform company, eventually becoming publicly traded on the Nasdaq under the ticker GUTS.